US-based Human Biosciences plans to launch 2 wound care products in India

US-based Human Biosciences plans to launch 2 wound care products in India

PTIUpdated: Sunday, September 05, 2021, 02:59 PM IST
article-image
The two products are named 'Medifil' and 'Skin Temp', the company said/ Representational image | Photo credit: Human Biosciences

The US-based Human Biosciences (HBS) on Sunday said it is planning to introduce two wound care products in the Indian market soon.

The two products are named 'Medifil' and 'Skin Temp', the company said in a statement.

It added that the company "plans to launch two of its wound care management products, 'Medifil' and 'Skin Temp', in India soon".

These products will be introduced with exclusive marketing and distribution channels, the statement said.

Some of its wound care products are already available in India that are manufactured at the company's unit in Ahmedabad, Gujarat, HBS said.

"Our mission at HBS is to provide customers with healthcare products of high quality at an affordable price.

"We are planning to set up more manufacturing units in India to increase production and expand our reach, so that more people can avail benefits of these products," HBS founder Manoj Jain was quoted as saying in the statement.

'Medifil' and 'Skin Temp' help stop bleeding and play active role in healing of the wound, he said.

RECENT STORIES

Foreign Portfolio Investors Invested $1.4 Billion In Last Five Sessions Post NDA Government...

Foreign Portfolio Investors Invested $1.4 Billion In Last Five Sessions Post NDA Government...

'It Will Be Epic': Tesla CEO Elon Musk Announces Tesla Master Plan 4; Netizens React

'It Will Be Epic': Tesla CEO Elon Musk Announces Tesla Master Plan 4; Netizens React

Google Unveiled It's Gemini AI In India With Support For Local Languages

Google Unveiled It's Gemini AI In India With Support For Local Languages

Fitch Raises India's GDP Growth Forecast For FY25 To 7.2%, Aligns With RBI's Expectations

Fitch Raises India's GDP Growth Forecast For FY25 To 7.2%, Aligns With RBI's Expectations

Paytm-Zomato Deal: Payment Company's Shares Sink 2% After Early Gains

Paytm-Zomato Deal: Payment Company's Shares Sink 2% After Early Gains